CClinicalTrials.gg
RecruitingNCT05404230OxaNeuroUpdated May 19, 2026

Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities

An interventional study of Fish oil and Corn oil in Peripheral Neuropathy and Colorectal Cancer, sponsored by Vejle Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Vejle Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.

Read the detailed description

The primary objective of the present study is to examine if a high dosage of n-3 PUFA reduces the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) 8 months after adjuvant oxaliplatin following surgery for high-risk colorectal cancer.

An additional aim is to investigate whether n-3 PUFAs have an effect on nutritional status, cognition and mental status. Inflammatory mechanisms and biomarkers of CIPN in skin biopsies and in blood will be explored.

02

Conditions studied

  • Peripheral Neuropathy
  • Colorectal Cancer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.
  • ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.
  • Written and orally informed informed consent

Exclusion criteria

Exclusion Criteria:

  • Inability to speak, read, and understand Danish.
  • Previous treatment with neurotoxic chemotherapy.
  • Neurological (including neuropathy) or psychiatric disorders, diabetes or other significant medical conditions.
  • Alcohol or drug abuse.
  • Sensory disturbances in the feet
  • Spinal stenosis.
  • Vascular disease (Fontaine grade II or more).
  • Known allergy to fish, fish oil or corn oil
  • Fertile patients not willing to use effective methods of contraception during treatment or abstinence.
  • Daily intake of oil supplements and not willing to stop during the trial period.
  • Lack of consent to skin biopsy
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Fish oil

    4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day. 4 capsules per day for 8 months

    Dietary Supplement: Fish oil

  • Placebo comparator
    Corn oil

    4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day. 4 capsules per day for 8 months. Corn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine.

    Dietary Supplement: Corn oil

Interventions

  • Dietary supplementFish oil

    Fish oil containing poly unsaturated fatty acids.

  • Dietary supplementCorn oil

    Corn oil

05

What researchers measure

Primary outcomes

  1. Incidence of chemotherapy induced peripheral neuropathy (CIPN) 8 months after start of adjuvant chemotherapy

    Number of patients who meet the criteria for CIPN: relevant symptoms evaluated by a medical doctor, incl one of the following: abnormal vibration test or, abnormal nerve conduction test by DPN check device or, abnormal pinprick test or, abnormal skin biopsy.

    Time frame: 8 months after start of adjuvant chemotherapy

Secondary outcomes

  1. Intensity of CIPN-related neuropathic pain 8 months after adjuvant chemotherapy according to the Numeric Rating Scale (NRS)

    Average over the past 24 hours measured by NRS (scale from 0-10 with 0=no pain and 10=worst pain imaginable)

    Time frame: 8 months after start of adjuvant chemotherapy

  2. Change in severity of CIPN from baseline to 8 months after start of adjuvant chemotherapy according to the EORCT QLQ-CIPN 20 questionnaire

    EORCT QLQ-CIPN 20 = the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy

    Time frame: 8 months after start of adjuvant chemotherapy

06

Study locations

4 of 4 sites recruiting
  • Department of Oncology, AAUH
    Aalborg, Denmark
    • Laurids Østergaard Poulsen · Contact
    Recruiting
  • Department of Oncology, AUH
    Aarhus, Denmark
    • Christian Hviid · Contact
    Recruiting
  • Department of Oncology
    Sønderborg, Denmark
    • Stinne Husum · Contact
    Recruiting
  • Department of Oncology, Vejle Hospital
    Vejle, Denmark
    Recruiting
07

References and documents

Publications

  • Gehr NL, Karlsson P, Timm S, Christensen S, Hvid CA, Peric J, Hansen TF, Lauritzen L, Finnerup NB, Ventzel L. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro). BMC Cancer. 2024 Feb 3;24(1):168. doi: 10.1186/s12885-024-11856-z. PubMed 38308227 ↗

Individual participant data

Plan to share: Yes — Due to restrictions related to Danish law protecting patient privacy, the data used in this study can be made available if it complies with GDPR and through an application to the Region of Southern Denmark

Supporting information: Study protocol, Sap, Icf, Csr

08

Registry details

Key details

Study ID
NCT05404230
Lead sponsor
Vejle Hospital
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Jul 15, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 19, 2026

Study contacts

Malene Nielsen, MD.
Contact
Malene.Nielsen6@rsyd.dk
+45 26823726
Karin Larsen
Contact
Karin.Larsen1@rsyd.dk
+ 45
Lise Ventzel, MD PHD
study director · medical doctor at Vejle Hospital, University Hospital of southern Denmark

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion